HOME >> BIOLOGY >> NEWS
Stem-cell therapy could have benefits and risks for heart-attack PTs

Two studies in this week's issue of THE LANCET raise questions about the feasibility and safety of stem-cell therapy for heart disease, suggesting that such treatments could have both benefits and drawbacks.

Adult haemopoietic stem cells give rise to blood cells, and are thought to be able to generate other types of cell. Recent studies have investigated the potential of stem cells to reverse heart damage caused by diseases such as acute myocardial infarction (heart attack). Use of granulocyte-colony stimulating factor (G-CSF) to mobilise stem cells has shown promise, but its safety has not been tested in patients with myocardial infarction.

Hyun-Jae Kang, Huo-Soo Kim, and colleagues from Seoul National University, Republic of Korea, studied 27 patients with stable myocardial infarction who underwent coronary stenting. After follow-up assessment in 11 patients, the investigators noted improved heart function in the seven who were randomly assigned to receive an infusion of their own peripheral blood stem-cells and G-CSF. However, an unexpectedly high rate of in-stent restenosis (recurrence of coronary artery narrowing) was seen in patients given G-CSF, either alone or in combination with stem-cell infusion, and therefore trial enrolment was stopped.

In a Research letter (p 783), Richard Vulliet from the University of California and colleagues report that after being injected with bone-marrow stem-cells, evidence of myocardial infarction was seen in the hearts of dogs.

In a Commentary (p 746), Hiroaki Matsuba (Kyoto University Hospital, Japan) notes that these potential complications should be investigated thoroughly before such methods are more widely used in patients.

Contact:
Dr. Hyo-Soo Kim, Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Republic of Korea. T) 82-2-760-2226; F) 82-2-766-8904; E) hyosoo@snu.ac
'"/>


Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
3-Mar-2004


Page: 1 2

Related biology news :

1. Stem-cell research and reproductive cloning laws should be separate
2. Stem-cell defect underlies common genetic disorder
3. Targeted therapy knocks out pediatric brain cancer in mice
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Columbia research to examine gene influence on severity of peridontal disease, therapy response
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. The search for a kinder, gentler chemotherapy
8. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
9. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
10. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
11. Jefferson Lab detector technology aids development of cystic fibrosis therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/1/2019)... (PRWEB) , ... July 30, 2019 , ... ... Behrens as the George B. and Joy Rathmann Professor in Bioprocessing and Director ... an innovative leader in the life sciences industry and possesses more than 25 ...
(Date:7/26/2019)... LOS ANGELES (PRWEB) , ... July 25, 2019 ... ... Verifocal™ platform, today announced the first mixed reality headsets to include a new ... SIGGRAPH 2019 Exhibition in Los Angeles, California (July 30 - August ...
(Date:7/21/2019)... ... July 20, 2019 , ... ... the release of the biggest software update in its history: VisualSpreadsheet Software ... a significant increase in productivity for its users. , Matching the ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 11, 2019 , ... Veterinary Regenerative ... Inc. (PSC) , has announced that their GMP facility for cell production is ... for manufacturing. This is an important milestone for VetStem as it expands ...
(Date:6/6/2019)... ... June 05, 2019 , ... WCCT Global, Inc ., ... industries, announced today that they will be receiving 3 awards at the 2019 CRO ... received 2 awards in the categories of overall Quality and Compatibility (Access to desired ...
(Date:5/31/2019)... Redwood City, California (PRWEB) , ... ... ... received allowance of our patent applications from the USPTO providing proprietary interest ... SYSTEM AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object Pharma, Inc., a ... acquisition of Metabiologics, Inc., a globally recognized leader in the production and sale ... rights to a full spectrum of botulinum neurotoxins, as well as a CDC ...
Breaking Biology Technology:
Cached News: